Akka sends mixed signals in Q2

Akka sends mixed signals in Q2

Akka surprised investors with a CC/CS revenue growth slowdown in Q2 2019: revenues were up 5.1% yoy at CC (vs. 6.6% in Q1). Utilization declined by 50 bps yoy, and attrition (excluding PDS Tech) was up by a massive 530 bps, to 23.3%.

EDAG issues a profit warning

EDAG issues a profit warning

EDAG issued last night a profit warning for its full-year 2019 operations. The company is now expecting revenue growth by approximately 1% (previous guidance 5%), an adjusted EBIT margin of 4%-5% (previously 5%-7%), and a net profit of EUR 10m.

Introducing our pharma R&D research

Introducing our pharma R&D research

We have highlighted several times that the pharmaceutical sector represents ~25% of all R&D spending globally, more than automotive and aerospace. Still, very few vendors service pharma clients, and when they do, they provide manufacturing-related engineering services but never target R&D departments.

Cognizant to acquire Zenith Technologies and strengthens its MES capabilities for the life science industry

Cognizant to acquire Zenith Technologies and strengthens its MES capabilities for the life science industry

Cognizant has been making more headlines in ER&D services, recently. Last month, we had mentioned its software product engineering services (PES) contract with PLM vendor AVEVA. This week, we are looking into Cognizant’s planned acquisition of Zenith Technologies. Zenith

Read More